Globus Medical PE ratio GMED

Share price divided by earnings per share over the last twelve months, since 2013.

Today, Oct 23, 2026: 20.8×
10-year median: 37.4×
Against its 10-year history: 6th; percentile: 0 is its lowest day, 100 its highest
10-year range: 17.4× to 242×
Peer median: 27.4×

Globus Medical's PE ratio is 20.8× as of Oct 23, 2026: a share price of $81.41 against $3.91 of earnings per share over the last twelve months.

That is below its ten-year median of 37.4×, lower than on 94% of days in the last ten years.

Over that time it ranged from 17.4× in Nov 2016 to 242× in Nov 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 27.4×.

PE ratio over time

median 37.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.8×	17.8×	30.5×
2025	28.5×	21.4×	137×
2024	123×	33.4×	242×
2023	34.4×	22.7×	52.7×
2022	49.2×	35.8×	54.2×
2021	39.9×	34.8×	73.6×
2020	70.9×	24.3×	71.1×
2019	40.6×	26.6×	40.6×
2018	30.0×	29.2×	47.9×
2017	37.4×	20.3×	37.4×
2016	20.3×	17.4×	23.6×
2015	25.8×	20.6×	27.8×
2014	27.0×	20.6×	36.1×
2013	27.2×	16.2×	27.2×

Against its peers

Companies in Medical - Instruments & Supplies nearest Globus Medical's size, closest first, today.

Company	PE ratio
GMEDGlobus Medical	20.8×
ALGNAlign Technology	26.9×
PODDInsulet	27.9×
COOCooper Companies	20.9×
PENPenumbra	79.7×
SOLVSolventum	10.4×
MSAMSA Safety	22.7×
MMSIMerit Medical Systems	38.6×
HAEHaemonetics	58.1×
VNTVontier	14.3×
BMIBadger Meter	35.3×
Peer median	27.4×

Where Globus Medical ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Globus Medical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.